Interline raises $92M for drug discovery of dysfunctional proteins

By The Science Advisory Board staff writers

Interline Therapeutics has raised $92 million to be used to expand its research platform and advance six preclinical therapeutic programs.

Foresite Capital and ARCH Venture Partners co-led the financing, which will be used to support platform development and therapeutic programs focused on inflammatory disease and cancer. Interline will use a combination of genomics, proteomics, structural biology, and computational chemistry to systematically map and modulate proteins to develop a precision medicine platform capable of correcting dysfunctional disease networks.

The company will continue to collaborate with Foresite Labs in the fields of data science and genomics. Interline also launched with foundational collaborations with University of California, San Francisco and Memorial Sloan Kettering Cancer Center, as well as an internationally recognized team of founding scientific advisors.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?